Incorporation of recombinant fibronectin into genetically engineered elastin-based polymers by Balderrama, Fanor Alberto






















In Partial Fulfillment 
of the Requirements for the Degree 
Master of Science in the 


























 Approved by: 
 
 Dr. Elliot L. Chaikof, Advisor 
 School of Biomedical Engineering 
 Georgia Institute of Technology 
 Department of Surgery 
 Emory University School of Medicine 
 Dr. Hanjoong Jo 
 School of Biomedical Engineering 
 Georgia Institute of Technology 
 Division of Cardiology 
 Emory University School of Medicine 
 
 Dr. Vincent P. Conticello 
 School of Chemistry 
 Emory University 
 










I would like to thank my advisor, Dr. Elliot Chaikof, for the opportunity of working on this 
research and for all the guidance.  I would also like to thank Dr. Carolyn Haller for all her 
priceless guidance, her supervision and patience, without which this thesis would have 
not been possible.   
My sincere appreciation goes out to members of my committee: Dr. Hanjoong Jo and Dr. 
Vincent Conticello for their help with the direction and the review of this thesis.   
I would also like to thank all the other members of the Chaikof laboratory for their 
friendship, their help and their advice, without which my research experience would have 
not been so enjoyable. 
Last, but absolutely not least, I thank my family for all their support (professional, 
















TABLE OF CONTENTS 
 
Acknowledgements iii 
List of figures vii 
List of abbreviations viii 
Summary x 
Chapter I: Introduction 1 
1.1. Specific Aims and Central Hypotheses 2 
Chapter II: Literature review 3 
 2.1. Biological Grafts 3 
  2.1.1. Autografts 3 
  2.1.2. Allografts 4 
 2.2. Synthetic Polymer Grafts 5 
  2.2.1. Expanded Polytetrafluoroethylene 6 
  2.2.2. Polyethylene Terephthalate 6 
 2.3. Biopolymers 7 
  2.3.1. Collagen 7 
  2.3.2. Elastin and LysB10 7 
v 
 
   2.3.2.1. Mechanical Importance of Elastin in  7 
     Vascular Tissue  
   2.3.2.2. Structure of Elastin and LysB10 8 
 2.4. Fibronectin and FNIII7-10 (rFN) 12 
 2.5. Integrins and Focal Adhesions 16 
 2.6. Cell Microenvironment Optimization in Tissue Engineering 18 
 2.7. Crosslinking Agents 20 
  2.7.1. Genipin 21 
Chapter III: Methodology 23 
 3.1. Protein Production 23 
  3.1.1. Expression and Purification of Recombinant Elastin 23 
  3.1.2. Expression and Purification of Recombinant  25 
             Fibronectin  
 3.2. Cell Adhesion Experiments 27 
  3.2.1. Testing the Biological Activity of rFN 27 
  3.2.2. Preparation of LysB10 Hydrogels 28 
  3.2.3. Passive Adsorption and Stable rFN 28 
   Incorporation onto LysB10 Surfaces 
 3.3. Cell Culture, Seeding and Quantification 29 
 3.4. Elisa and rFN Immobilization Efficiency 30 
vi 
 
 3.5. Immunostaining for Vinculin and Actin 31 
Chapter IV: Results 33 
 4.1. Fibronectin and rFN Show Similar Biological Activity 33 
 4.2. LysB10 Hydrogels Cannot Support Cell Adhesion 39 
 4.3. LysB10 Hydrogels Support Cell Adhesion in the 41 
        Presence of rFN 
 4.4. LysB10 Can Be Stably Modified with the Incorporation of rFN 43 
Chapter V: Discussion 52 
















LIST OF FIGURES 
 
Figure 2-1 Nucleotide and amino acid sequence of LysB10 11 
Figure 2-2 Amino acid sequence of rFN organized by domains 15 
Figure 4-1 Purification of rFN 35 
Figure 4-2 Immunostaining for cell adhesion activity to rFN  36 
 and hpFN  
Figure 4-3 Cell-adhesive activities of rFN and hpFN compared 37 
Figure 4-4 Cell-adhesive activity of rFN at different coating  38 
 concentrations  
Figure 4-5 Cell adhesion to LysB10 hydrogels 40 
Figure 4-6 Cell adhesion to LysB10 hydrogels in the presence of rFN 42 
Figure 4-7 Crosslinking efficiency of rFN onto LysB10 hydrogels 45 
Figure 4-8 Immunostaining for cell adhesion activity to untreated  46 
 and modified hydrogels  
Figure 4-9 Cell adhesion to modified LysB10 Hydrogels 47 
Figure 4-10 Cell adhesion to modified LysB10 hydrogels at  48 
 different rFN concentrations  
Figure 4-11 Endothelial cell proliferation on modified, coated and  50 
 untreated hydrogels   




LIST OF ABBREVIATIONS 
 
BBP BSA-blocked polystyrene 
BSA Bovine serum albumin 
CVD Cardiovascular disease 
ECM Extracellular matrix 
EDC 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide  
ePTFE Expanded polytetrafluoroethylene 
GPX Genipin-crosslinked FNIII7-10 onto LysB10 hydrogels 
hpFN Human plasma fibronectin 
HRP Horseradish peroxidase 
HUVEC Human umbilical vascular endothelial cell 
IPTG Isopropyl beta-D-1-thiogalactopyranoside 
NGF Nerve growth factor 
PAG Passively adsorbed rFN onto LysB10 hydrogels 
PBS Phosphate buffer solution 
PEI Poly(ethyleneimine) 








rFN Recombinant fibronectin (FNIII7-10) 
RGD Arginine-glycine-aspartic acid peptide sequence 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
Strep-AP Streptavidin-alkaline phosphatase conjugate 
Sulfo-SMCC Sulfosuccinimidyl 4-[N-maleimidomethyl] 
 cyclohexane-1-carboxylate  














This thesis describes a new complex biomaterial that combines recombinant 
elastin and fibronectin proteins in a covalently crosslinked hydrogel.  This material is 
intended to be applied in vascular grafts, and it is with this objective in mind that the two 
proteins were chosen.  Elastin, along with collagen plays an important role in the 
mechanical properties of vasculature.  Fibronectin has been extensively studied for its 
cell-binding properties and its ability to promote tissue integration when incorporated on 
biomaterials.  The resulting material consists on a porous elastin-mimetic hydrogel 
presenting the cell-binding domains of fibronectin.  
First, it was assessed that recombinant fibronectin (rFN) preserves similar cell 
binding capabilities of human plasma fibronectin through cell adhesion assays where 
human umbilical vein endothelial cells (HUVECs) were used.  Furthermore, it was 
observed that when coating inert surfaces, greater concentrations of rFN resulted in 
greater numbers of cells adhered to these surfaces, indicating that rFN was responsible 
for the increase in cell adhesion.  By means of these adhesion tests, it was also 
observed that elastin mimetic hydrogels without rFN did not support significant levels of 
cell adhesion.  Recombinant fibronectin was chemically crosslinked and incorporated 
onto elastin mimetic hydrogels, and the modified substrates supported cell adhesion and 






Cardiovascular disease is the main cause of death in the United States.  Many of 
these conditions require the grafting or bypassing of compromised blood vessels.  To 
this effect, biological vascular grafts, those obtained from the same patient (autologous) 
or from a member of the same species (allogeneic), are the first line of action.  However, 
when the patient lacks vasculature suitable for grafting use, several synthetic grafting 
options are available.  
The search for an inert biomaterial for vascular grafts has proven to be 
unsuccessful.  This makes the interactions taking place on the blood-biomaterial 
interface critical for the success of the grafts.  While synthetic polymers are the most 
common group of materials for the fabrication of vascular grafts, several biosynthetic 
materials have been developed.  This thesis introduces a new bio-inspired approach to 
tackle the mechanical and biological challenges of vascular material design. 
The hypothesis of this research is that recombinant fibronectin protein can be 
stably incorporated onto elastin-mimetic polymers to increase endothelialization.  A 
recombinant version of elastin, designed to recreate the mechanical properties of natural 
elastin, was used for the preparation of hydrogel surfaces.  These surfaces showed low 
levels of endothelial cell adhesion.  For immobilization of recombinant fibronectin, 
genipin, a chemical crosslinker, was used to covalently link the protein to the elastin-
mimetic material.  The crosslinked surfaces showed high levels of cell adhesion, and 
unlike unmodified surfaces simply coated with fibronectin, this biological effect was 
stable.   
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Specific Aims and Central Hypothesis 
 
The central hypothesis in this study states that recombinant fibronectin can be used to 
functionalize elastin mimetic protein substrates for improving endothelialization.   This 
Central Hypothesis was investigated by pursuing the following specific aims. 
The goal of specific aim 1 was to synthesize recombinant fibronectin and 
characterize its biological activity on an elastic mimetic surface.  We hypothesized that 
the cell-adhesive activity of our fibronectin protein variant is comparable to natural 
fibronectin.  It was proved that coating inert surfaces with both proteins increased their 
cell-adhesion levels in a similar manner.  Based on that hypothesis, we later proved a 
second hypothesis for this specific aim, that recombinant fibronectin promotes 
endothelialization on elastic mimetic surfaces. 
The goal of specific aim 2 was to achieve a stable incorporation of recombinant 
fibronectin onto the elastic mimetic surfaces.  Based on the sequences of both proteins, 
it was hypothesized that elastin surfaces could be covalently modified with recombinant 
fibronectin.  This objective was achieved with the use of genipin for the crosslinking of 
both fibronectin and elastin recombinant proteins.  It was also hypothesized that by 
crosslinking our fibronectin protein variant, its cell-adhesive effects would be retained on 
elastin mimetic substrates.  After long incubation, chemically modified surfaces retained 
the same cell-adhesive activity, while this activity was largely lost on coated elastin 
mimetic surfaces over the same period of time. 
 







According to the American Heart Association Heart Disease and Stroke 
Statistics-2009 Updates, cardiovascular disease (CVD) imposes an extraordinary 
socioeconomic cost in the United States.  CVD is currently the leading cause of death 
among Americans, accounting for approximately 35.3 percent of all deaths in the US (1 
in every 2.8 deaths), and in 2008 had an associated cost of $475.3 billion.  Coronary 
heart disease (CHD) accounts for 52% of all CVD-related deaths.  In 2006 alone, 
roughly 440,000 cardiac bypass surgery procedures were performed in 253,000 patients 
in the US [1, 2].   
 
2.1. Biological Grafts 
 
2.1.1. Autografts 
It is estimated that 1.4 million patients in the US present arterial tissue 
deficiencies [3, 4].  Autologous grafts (autografts) are currently the method of choice for 
vascular replacements in both coronary bypass and peripheral grafting surgeries, 
generally performing better than synthetic alternatives [5-7].  Patency rates, the 
likelihood a vascular grafts will remain unblocked, is the most common criteria used to 
describe the degree of success of grafts.  By these terms, autografts have been reliable 
in cases where they can be applied.  The use of the gastropiploic artery for coronary 
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bypass has been reported to yield 1-, 3- and 5- year patency rates of 98.7, 91.1 and 
84.4%, respectively.  In similar applications, the same patency rates for the usage of the 
left internal mammary artery are estimated at 99.6%, 98.8 % and 97.0 % [8].  Other 
common and successful arteries and veins used for autografts include the radial artery, 
the saphenous vein, the internal jugular vein and the ipsilateral great saphenous vein, 
with arterial autografts being usually more successful (in terms of patency rates) than 
venous grafts [5].  In general, the limitations of autografts are associated with tissue 
availability.  Not every healthy vessel is suitable for use as grafts, and the use of 
different arteries and veins has met different rates of success, depending also on the site 
of application.  In general, grafting success rate decreases as vasculature decreases in 
diameter.  The length and nature of the lesion can further limit the grafting options.  
Depending on the procedure, up to 30% of patients do not have vasculature suitable for 




When autografts are not an option, allogeneic transplantation is the most 
common second line of action.  The use of these grafts, however, presents its own 
challenges.  In order to reduce the risk of viral disease transmission from allografts, 
these are frozen and cryopreserved for several months.  The cryopreservation process 
has been linked to mechanical rupture and aneurysm formation in the grafts in the short 
term after transplantation, from a few hours to 1 month [9].  Early allografts, especially 
for peripheral arterial bypass showed mixed rates of success, as measured by patency 
rate [10, 11].  Failure was attributed to immune reactions.  Allograft tanning with 
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glutaraldehyde has proved to be a useful way of increasing tensile strength and 
flexibility, masking histocompatibility antigen sites and reducing the risk of allograft 
biodegradation [12].  It has been suggested, however, that glutaraldehyde leaching can 
cause delayed biodegradation (due to the loss of crosslinking sites), cytotoxic effects on 
fibroblasts and foreign body giant cell response [13].  Despite the major improvements 
from tanning, the 5-year patency rate of these grafts drops in comparison to autografts, 
down to 67% [5].   
 
2.2. Synthetic Polymer Grafts  
 
Synthetic substitutes have evolved to imitate many of the functions and 
characteristics of natural tissue.  The ideal vascular graft, as defined by Kannan, must 
be nonthrombogenic, compatible at high blood flow rates, and have similar 
viscoelasticity to native vessels [14].  The search for a non-reactive biomaterial has 
proven to be unsuccessful.  Biomaterial research has focused on optimizing the 
interaction with tissue to elicit a controlled reaction and desirable results [15].  The 
efficacy of these materials in grafts is determined by the blood-biomaterial interface and 
the mechanical profile match between native vasculature and the biomaterial [16].  
Synthetic materials currently employed in vascular grafts include expanded 
Polytetrafluoroethylene (ePTFE), Dacron ® (DuPont, DE, USA) and polyurethanes (PUs) 






2.2.1. Expanded Polytetrafluoroethylene 
The high crystallinity and hydrophobicity of ePTFE make it a logical choice for a 
biomaterial.  These properties have important implications in predicting the interactions 
between the surface of the biomaterial and blood.  Its hydrophobicity prevents hydrolysis 
of the polymer chains and biodegradation of the material within the body.  Its 
electronegativity minimizes its interaction of the material surface with blood [15].  It 
presents a microporous structure, which is more suitable for cell adhesion and tissue 
integration than the non-expanded form of polytetrafluoroethylene (PTFE) [14].  ePTFE 
grafts have greater success when used on large diameter vessels. They perform with a 
5-year patency rate of 91% when used as aortic bifurcation grafts [17], but the patency 
rate drops down to 45% when they are employed for above-knee femoropopliteal bypass 
[18].  In comparison, autografts perform with a patency rate of 77% in the latter situation 
[15].     
 
2.2.2 Polyethylene Terephthalate 
Polyethylene terephthalate (PET) or Dacron ®, as it was introduced by DuPont in 
1939 is a synthetic polymer implemented as either knitted or interwoven multifilament 
fibers for the making of vascular graft.  The porosity of PET grafts is such that the 
material needs to be preclotted (a process that has been performed with collagen, 
gelatin and albumin in commercially available grafts) to prevent transmural blood 
extravasation [14, 19].  Similar to ePTFE, PET possesses a highly crystalline structure 
and hydrophobic properties [15].  PET aortic bifurcation grafts perform with a 5-year 
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patency rate of 93% [20].  Comparably to PTFE grafts, however, the 5-year patency rate 




An elegant alternative to synthetic polymers for vascular grafts is the use of ECM 
proteins that make up part of the native architecture of blood vessels [21].  One of the 
most studied ECM proteins for this application is Type I Collagen.  Type I Collagen is an 
attractive material for vascular grafts due to its resistance to rupture [22] and critical 
contribution to the overall elastic modulus of native vasculature, especially at high 
pressures [23].  Natural collagen also shows potential for endothelialization applications.  
Davis and Camarillo reported that upon been seeded on Type I collagen gels, human 
endothelial cells formed capillary networks.  This process was dependent on alpha-2-
beta-1 integrin cell surface receptors [24, 25], and has, since then, been mapped to a 
specific integrin-binding amino acid sequence in collagen [26].  
Several approaches have been taken to improve mechanical strength of collagen 
constructs and avoid degradation [5, 21], necessary steps to make them suitable for 
vascular grafts.  These approaches include glutaraldehyde crosslinking [27] (though the 
risks associated with leaching are still a concern [21]) and mechanical conditioning [28]. 
 
2.3.2. Elastin and LysB10 
2.3.2.1. Mechanical Importance of Elastin in Vascular Tissue 
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Elastin and collagen are key structural proteins in the extracellular matrix of 
vasculature [29], and the mechanical properties of vascular tissue can be attributed to 
these two proteins and to smooth muscle cells [23, 30].  Collagen provides the tissue the 
stiffness necessary to withstand blood pressure and limit deformation during excessive 
strain [30, 31]. Smooth muscle acts as a force-generating component in vasculature 
under physiological regulation [23, 32].  Elastin provides vasculature with compliance 
and resilience (distensibility and elastic recovery) necessary to absorb the hemodynamic 
stress during cardiac systole and release the energy in the form of sustained blood 
pressure during diastole [33].  
The interplay of elastin and collagen proteins defines to a great extent the 
mechanical properties of blood vessels and their critical importance for circulation.  
Compliance influences pulse pressure. Ultimately, the limits of organ perfusion are set 
by the pressure-dependent caliber of blood vessels at full dilation [34] . 
2.3.2.2. Structure of Elastin and LysB10 
Given the importance of elastin, this protein is a natural choice for a bio-inspired 
vascular material.  Human elastin is synthesized as a 72 kDa soluble precursor, 
tropoelastin.  Tropoelastin, though varying between species and tissue location, 
generally presents an extremely apolar structure.  It is rich in glycine (30-33%), valine 
(15-18%), proline (10-13%) and other hydrophobic residues (28%) [35, 36].  
Recombinant materials allow for a fine tuning of macroscopic characteristics by 
accessing diverse morphologies [37, 38].  Urry and colleagues, for instance, explored 
the changes in temperature-dependent behavior brought about by the substitution of a 
single residue in a basic repeat unit in an elastin-mimetic protein (poly (Val-Pro-Gly-Val-
Gly)) where the amino acid in the fourth position is substituted).  They observed that the 
temperature of reversible self-aggregation could change ranging from 5°C to 40°C 
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depending of the hydrophobicity of the amino acid and the frequency of the substitution 
[39].  Unlike other proteins, which undergo denaturation and loss of function, elastin and 
its recombinant variants respond to an increase in temperature by undergoing reversible 
self-aggregation and forming insoluble fibrillar networks [40], a phenomenon known as 
coacervation [39]. 
Our group has developed a new type of elastin-mimetic protein named LysB10.  
Morphologically, the protein is a multiblock polymer comprised of two hydrophobic 
blocks flanking and a central hydrophilic block [35].  This molecular arrangement allows 
for the formation of self-assembled networks [38].  The self-aggregating hydrophobic 
blocks (predominantly Ile-Pro-Ala-Val-Gly repeats) display plastic-like mechanical 
properties.  These blocks flank a central block that is elastomeric in mechanical nature 
(Val-Pro-Gly-Xaa-Gly, where Xaa is Ala- or Glu-  in a 4:1 ratio) [38, 41] (Figure 2-1).  At 
physiologically relevant conditions (pH ~7.4 and 37 C), the multiblock polymer is present 
in coacervated form.  Physical or non-covalent crosslinks are formed from the 
aggregation of hydrophobic blocks and the self-association of chemically similar 
domains [41, 42].   
In elastin and elastin-mimetic proteins, the hydrophobic blocks are responsible 
for self-aggregation and tensile properties.  In contrast, the hydrophilic or crosslinking 
blocks, take part in covalent zero-length crosslinking [43]. Elastin, as found in tissue, is 
in a crosslinked form.  Rapidly after tropoelastin is secreted into the extracellular space, 
it becomes insoluble. The enzyme lysyl oxydase catalyzes an oxidative deamination of 
lysine residues in tropoelastin in vivo to produce allysine residues [44].  Next, closely 
positioned lysine and allysine residues from adjacent tropoelastin chains undergo 
spontaneous condensation to produce covalent crosslinks such as allysine aldol, 
lysinonorleucine, merodesmosine, and tetrafunctional crosslinks desmosine and 
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isodesmosine [44-46].  To account for the chemical crosslinking in elastin, small lysine-
carrying inserts were introduced between the hydrophobic and hydrophilic blocks in the 
primary sequence of LysB10 [35] (Figure 2-1).  In this study, these lysine groups were 
targeted for crosslinking.  Genipin was used to react with the amine groups on the side 














Val  Pro  Ala   Val  Gly  Lys  Val  Pro  Ala   Val  Gly  Ile  Pro  Ala   Val  Gly  Ile 
GTT  CCA  GCT  GTT  GGT  AAG  GTT  CCA  GCG  GTT  GGT  ATC  CCA  GCC  GTG  GGT  ATC 
Pro  Ala   Val  Gly  Ile  Pro  Ala   Val  Gly  Val  Pro  Ala   Val  Gly  [Ile  Pro  Ala  
CCA  GCG  GTT  GGC  ATT  CCG  GCC  GTA  GGC  GTA  CCG  GCG  GTT  GGT  [ATT  CCA  GCG 
Val  Gly  Ile  Pro  Ala   Val  Gly  Ile  Pro  Ala   Val  Gly  Ile  Pro  Ala   Val  Gly 
GTT  GGT  ATC  CCG  GCC  GTG  GGT  ATC  CCA  GCG  GTT  GGC  ATT  CCG  GCC  GTG  GGC 
Val  Pro  Ala   Val  Gly]33  Ile  Pro  Ala   Val  Gly  Lys   Ala   Ala   Lys   Ala   Pro  Gly  
GTA  CCG  GCG  GTT  GGT]33  ATT  CCA  GCT  GTT  GGT  AAG  GCG  GCC  AAG  GTT  CCA  GGT 
Ala   Gly  [Val  Pro  Gly   Ala   Gly  Val  Pro  Gly   Ala   Gly  Val  Pro  Gly  Glu  Gly 
GCA  GGC  [GTT  CCA  GGT  GCA  GGC  GTA  CCG  GGT  GCT  GGC  GTT  CCG  GGT  GAA  GGT 
Val  Pro  Gly  Val  Gly  Val  Pro  Gly  Val  Gly]28  Val  Pro  Ala   Val  Gly  Lys   Ala  
GTT  CCA  GGC  GCA  GGT  GTA  CCG  GGT  GCG  GGT]28  GTT  CCA  GCT  GTT  GGT  AAG  GCG 
Ala   Lys  Val  Pro  Gly   Ala   Gly  Val  Pro  Ala   Val  Gly  Ile  Pro  Ala   Val  Gly 
GCC  AAG  GTT  CCA  GGT  GCA  GGC  GTT  CCA  GCT  GTT  GGT  ATC  CCA  GCT  GTT  GGT 
Ile  Pro  Ala   Val  Gly  Ile  Pro  Ala   Val  Gly  Ile  Pro  Ala   Val  Gly  [Ile  Pro 
ATC  CCA  GCT  GTT  GGC  ATT  CCG  GCT  GTA  GGT  ATC  CCG  GCA  GTG  GGC  [ATT  CCG 
Ala   Val  Gly  Ile  Pro  Ala   Val  Gly  Ile  Pro  Ala   Val  Gly  Ile  Pro  Ala   Val 
GCT  GTT  GGT  ATC  CCA  GCT  GTT  GGT  ATC  CCA  GCT  GTT  GGC  ATT  CCG  GCT  GTA 
Gly  Ile  Pro  Ala   Val  Gly]33  Ile  Pro  Ala   Val  Gly   Lys  Ala   Ala   Lys  Ala   Stop 
GGT  ATC  CCG  GCA  GTG  GGC]33 ATT  CCA  GCT  GTT  GGT  AAG  GCG  GCC  AAG  GCG  TAA 
 





2.4 Fibronectin and FNIII7-10 (rFN) 
 
Endothelialization is critical for the success of non-biological vascular grafts.  
Herring and Mansfield suggested that endothelialization would provide a more 
biocompatible surface and thereby decrease thrombosis and intimal hyperplasia [7, 47, 
48]. It has been shown since then that cell-seeded grafts develop an extensive 
endothelial lining after implantation [49].   In a randomized clinical study, Deutsch and 
colleges report a primary 9-year patency rate of 68% for ePTFE grafts seeded with 
autologous endothelial cells and a rate of 16% for unseeded ePTFE grafts (both groups 
of patients received above-the-knee and bellow-the-knee graftings) [50].  Thrombosis, 
patency loss, intimal hyperplasia, and ultimately stenosis have hindered the success of 
synthetic materials in vivo, especially when used on small diameter vasculature (> 5mm) 
[51].  These processes, however, can be reduced by endothelializing the graft lumen, 
thereby, decreasing protein deposition and infection [49, 51].  Low endothelial cell 
seeding on synthetic polymeric surfaces, such as ePTFE or Dacron ®, does not suffice 
for in vivo applications.  High cell densities are necessary before any implantation as 
pulsatile flow can detach up to 70% of the seeded cells within 45 minutes after exposure 
[51, 52].  Hence, improving cell adhesion, retention and proliferation in synthetic and 
other type of materials is a very active field of vascular tissue engineering research. 
Some of the approaches used to increase endothelialization include mechanical 
[28] or electrostatic pre-conditioning of synthetic materials [53].  The tissue engineering 
approach postulated in this thesis, however, involves the incorporation of specific 
biological adhesion cues onto our basal elastin mimetic material.  The adhesion cue 
chosen for our studies is FNIII7-10, a recombinant form of fibronectin developed by the 
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Erickson group [54].  Fibronectin is a well studied glycoprotein of the extracellular matrix 
(ECM), and it is found in connective tissue throughout the body in humans and in blood 
plasma [55, 56].  Fibronectin is also expressed as a membrane glycoprotein in some 
cells, and fibronectin-like domains are found in large glycoprotein complexes in the 
ECM, such as tenascin [57].  Fibronectin can be found in monomeric and dimeric forms 
ranging in size from 146,000 to 450,000 Da.  Being a major extracellular connective 
tissue component, fibronectin is distributed extensively on basement membranes [54].   
The importance of fibronectin for cell adhesion is illustrated in seminal work that 
identified fibronectin as a single serum component required for fibroblasts to adhere to 
collagen substrates in vitro and display the morphological changes associated with cell 
adhesion (flattening and spreading) [58].  FNIII7-10 (hereafter referred to as rFN), was 
designed after the type III domains 7 through 10 of fibronectin [54, 56, 59].  Of special 
importance within these domains are two cell-binding amino acid sequences, Arg-Gly-
Asp (RGD) and Pro-His-Ser-Arg-Asn (PHSRN), located in the tenth and ninth domain, 
respectively [60, 61] (Figure 2-2).   
RGD is one of the best understood recognition sites in cell adhesion.  This 
ubiquitous tripeptide sequence has been found in fibronectin, vitronectin, type I collagen, 
von Willebrand factor, osteopontin and in platelet adhesion proteins, among others, 
where it plays a critical role in cell adhesion and migration [62].  RGD containing 
peptides have been coated onto synthetic surfaces, resulting in the promoting of 
fibronectin-like cell adhesion onto otherwise cell-inhospitable substrates [63-65].  
Furthermore, RGD-containing peptides in solution are capable of blocking cell adhesion 
by binding and occupying the RGD recognition sites on cell membrane receptors.  Even 
the smallest alterations in the tripeptide sequence, such as replacing alanine for glycine 
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residue or aspartic acid for the glutamic acid residue, can eliminate these cell binding 
phenomena [66]. 
The role of PHSRN, on the other hand, is only complementary, i.e. synergistic 
only, to RGD.  In competitive binding assays, peptides containing RGD and PSHRN in 
solution blocked cell binding to fibronectin-coated surfaces better than peptides 
containing only RGD, while peptides containing only PHSRN did not show significant 
inhibitory activity  [60].  Petrie and Garcia suggest that PHSRN may play a role in the 
integrin binding specificity.  They report that both RGD and PHSRN sites, and only in the 
same spatial context within the type III domains of fibronectin, are necessary for specific 
binding to alpha-5-beta-1 integrin cell receptors.  Other synthetic peptides presenting 
RGD only, and even RGD and PHSRN sites combined, promote binding to alpha-v-beta-
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2.5. Integrins and Focal Adhesions 
 
Integrins are the most important cell receptors for the extracellular matrix.  
Integrins are also signal transduction receptors, relaying information about adhesive 
ligands to control cell growth and structure [67].  Their name denotes the role they play 
linking the ECM and the cytoskeleton, though integrins regulate many more aspects of 
cell behavior other than cytoskeleton [68].  Fibronectin binds to at least nine different 
integrins.  Both laminin and von Willebrand's factor bind to at least five different integrins.  
This promiscuity may reflect common motifs, such as RGD, in otherwise unrelated 
ligands [67]. 
Structurally, integrins are heterodimers of one of 18 alpha subunits and one of 8 
beta subunits [68], both having large extracellular segments and short transmembrane 
and cytoplasmic segments [69].  Both subunits contribute to binding specificity, which 
allows for a combinatorial strategy to establish an integrin repertoire [67].  In this 
manner, alpha-2-beta-1 integrins binds to Type-I collagen [70] and to certain fibronectin 
species, though not by RGD binding.  Alpha-v-beta-3 integrins bind to fibrinogen and 
fibronectin through RGD sequences in the ECM proteins [67, 71]. Of special importance 
for this study is the observation by Petrie and colleagues that rFN binds to fibroblasts 
primarily by alpha-5-beta-1 integrins with great specificity through RGD and PHSRN 
sequences [61], and the demonstration by Dormond et al. that the same integrins are 
present in HUVEC and constitute the principal receptor involved in the binding of 
HUVEC to fibronectin [72].  
Fibronectin binding to integrin is followed by conformational changes on integrin 
[69] that result in the interaction with many signaling and structural proteins.  Integrin-
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fibronectin complexes cluster together on specialized nodes called focal contacts, where 
they aggregate with cytoskeletal adapter proteins called talin and vinculin on the 
cytoplasmic side of the cell membrane [67, 73].  These nascent adhesive structures 
mature into focal adhesions upon interaction with cytoskeletal proteins of which the most 
important is actin [73].  Ultimately, more than 50 different proteins can be found either 
stably or temporarily associated to focal adhesions, not to mention that many others can 
affect the structure of focal adhesions without being physically attached to them [74].   
Focal adhesions are flat, elongated structures of several microns in length, often 
located on the periphery of cells.  They mediate strong attachments to the substrate and 
anchor bundles of actin filaments [75].  Actin can be found in polymerized filaments or in 
monomeric form.  Polymerization of actin supports plasma membrane protrusions [67].  
This protrusion is the first step on a series of events taking part in cell adhesion, spread 
and migration processes [76].  Next, a cell attachment to a substratum takes place.  This 
happens, for example, during the binding of fibronectin to integrins.  Then focal 
adhesions are formed to link the substratum to the cytoskeleton.  Finally traction is 
created in which the bulk of the trailing cytoplasm is drawn forward [77].  Ponti and 
colleagues determined that while lamellipodia formation is a random process caused by 
actin polymerization in a random trajectory, these temporary structures are 
disassembled quickly.  Productive cell spreading takes place when lamillipodia formation 
is accompanied by adhesion to ECM ligands and formation of focal adhesions [76].  In 
addition, migration takes place when the process includes the disruption of older 
adhesion sites at the cell rear and cytoskeleton retraction [78].  The formation of actin 
fibers and recruitment of vinculin on focal adhesions are phenomena that were used to 




2.6 Cell Microenvironment Optimization in Tissue Engineering 
 
The ultimate goal of tissue engineering is the restoration of organ and tissue 
function through the delivery of living components which become integrated into the 
patient [3].  The importance of this approach is clearly exemplified by the 
endothelialization of vascular grafts and its influence in the success of these devices 
[50].  Several approaches have been taken to promote cell adhesion, migration, 
proliferation and phenotypic differentiation on biomaterials [51, 63].  Such approaches 
can be mechanical, spatial, chemical or biological.  For instance, Stegeman and Nerem 
report that, when exposed to different combinations of mechanical conditioning and 
exposure to growth factors, tubular collagen constructs seeded with smooth muscle cells 
changed their cell proliferation rate and alpha-actin expression levels.  Cyclic mechanical 
strain also caused the seeded cells to align, and addition of different growth factors 
caused the construct to develop into looser or denser matrices [79].  There are 
numerous reports about the importance of scaffold architecture for cell support.  Mandal 
and Kundu report that silk fibroin scaffolds of different porosities produce different rates 
of cell adhesion and proliferation.  The spatial features of the scaffold influencing the cell 
population were not limited to pore size, but also included overall porosity and 
interconnectedness of the porous structures [80].   
In a similar note, bioactive molecules have been added onto microenvironments 
and surfaces made from synthetic polymers.  The simplest approach has been the 
passive release of these molecules from a source, such as porous polymeric matrices, 
that also serves as a substrate for cell growth [81].  A major inconvenience with this 
diffusible approach, however, is the instability of the concentration gradient.  Chemical 
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immobilization can stabilize the distribution of these biomolecules [82, 83].  Shoichet and 
colleges, for example, reported that rat adrenal PC12 cells, which upon treatment with 
nerve growth factor (NGF) stop dividing and terminally differentiate [84], developed 
longer and stronger neurites when cultured on poly(2-hydroxyethylmethacrylate) 
[p(HEMA)] surfaces with chemically crosslinked NGF than on unmodified versions of this 
surface on the presence of soluble growth factor [85].  Prior to the development of their 
chemical immobilization method, a diffusible system was employed to study the neurite 
growth response to NGF concentration gradients.  The unstable concentration in this 
type of diffusible system would pose great challenges for any in vivo application.  The 
translation of these chemically crosslinked systems into therapeutical devices was the 
motivation behind the development of chemical crosslinking techniques [86].    
Chemical immobilization of biofunctional peptides, such as those that promote 
cell adhesion, holds several advantages over diffusible passive adsorption from a 
biomaterial design standpoint [87]. First, covalent bonding is stronger and more stable 
than the interactions holding passively adsorbed peptides onto a surface, which can be 
overcome by shear forces, competitive adsorption with other proteins and proteolysis 
[88].  Second, the protein immobilization can be designed to preserve the accessibility of 
the peptide's binding site to cells, while passively adsorbed peptides might occlude the 
binding site [89, 90].  Finally, the choice of peptide and chemical linker can control 
directionality of the peptide, as well as the distance from the peptide to the surface [89]. 
With orthopedic and dental applications in mind, Petrie and colleges have 
successfully immobilized FNIII7-10 and RGD-containing peptides onto titanium-coated 
surfaces by chemical means.  This functionalization technique was applied on modified 
titanium implants in vivo, showing significantly improved functional oseointegration (as 
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measured by bone-implant contact area) with FNIII7-10 presenting implants over those 
modified with RGD peptides and untreated ones [91]. 
Immobilization of cell-binding peptides has also been applied on crosslinked 
elastin-mimetic hydrogels.  Kaufmann and Weberskirch, for instance, reported the 
immobilization of linear and cyclic RGD-containing moieties (oligopeptides conjugated to 
different spacers and functional groups) onto an elastic mimetic protein network.  They 
used different crosslinkers for the elastin mimetic network and for the incorporation of 
RGD-containing moieties.  They report that unmodified elastin mimetic hydrogels 
constitute inert surfaces to cell adhesion.  The study also discusses the importance of 
the context on which RGD is presented, i.e. in linear or cyclic peptides and with or 
without the use of spacers [64].  Welsh and Tirrell have incorporated Arg-Asp-Gln-Val 
and RGD-containing peptides (both derived from fibronectin) directly into the primary 
sequence of their elastin mimetic protein by means of cloning.  The crosslinkable elastin-
mimetic and fibronectin-derived moieties have given these proteins the ability to form 
hydrogels of tunable mechanical properties and to support cell adhesion and migration 
[16, 92-94].   
 
2.7 Crosslinking Agents 
 
Crosslinkers are chemical reagents that create covalent or ionic bonds between 
polymer chains or, potentially, between segments of the same polymer chain.  For the 
purpose of protein crosslinking, crosslinkers can be classified in three categories: 
heterobifunctional, homobifunctional and zero-length crosslinkers [95].   
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In general, crosslinkers react with functional groups on amino acid residues or with the 
carboxyl or amino terminal groups on proteins.  In the case of heterobifunctional and 
homobifunctional crosslinkers, the reaction incorporates a covalent spacer between the 
two crosslinked groups.  A homobifunctional crosslinker contains two identical reactive 
groups [96].  Examples of this category include 3,3´-Dithiobis 
(sulfosuccinimidylpropionate)  (DTSSP) and pentanedial (glutaraldehyde) [97].  In 
contrast, a heterobifunctional crosslinker contains two different reactive groups [96].  
These are more commonly used than homobifunctional crosslinkers, and some 
examples of this category include Dimethyl 3,3´-dithiobispropionimidate•2 HCl (DTBP) 
and Sulfosuccinimidyl 4-[N-maleimidomethyl]cyclohexane-1-carboxylate (sulfo-SMCC) 
[97]. 
When zero-length crosslinkers are used, a direct joining of two groups is induced 
without the introduction of any additional material, by, for example, the formation of an 
amide linkage, without the introduction of any extrinsic material.  Some commonly used 
zero-length crosslinkers include carbodiimides like 1-ethyl-3-[3-dimethylaminopropyl] 
carbodiimide (EDC) that form amide linkages and others like cupric di(1,10-
phenanthroline) and 2,2’-dipyridyldisulfide, that form disulfide bonds [96]. 
 
2.7.1 Genipin 
For the purpose of this study, genipin was used to crosslink recombinant elastin 
meshworks and for the incorporation of rFN.  Genipin is a naturally occurring 
crosslinking agent extracted from the fruits of the common gardenia (Gardenia 
jasminoides), a flowering tropical plant, and it is classified as an iridoid glucoside [98].  It 
is a crosslinker that reacts with primary amine groups.  In protein crosslinking, it reacts 
mainly with the terminal primary amines in the side chains of lysine residues.   Butler and 
colleges suggest that crosslinking takes place between primary amines and two reactive 
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sites in the genipin molecule.  The first reaction is a nucleophilic attack of the genipin 
from a primary amine group that leads to the formation of a heterocyclic compound of 
genipin linked to the basic residue.  The second reaction is a nucleophilic substitution of 
the ester group in genipin to form an amide link to the amino acid side chain and to 
release methanol.  Genipin, however, also becomes polymerized in the crosslink 
formation through an oxidative reaction [99].  An inherent phenomenon in the 
crosslinking reaction is the oxygen radical-induced self-polymerization of genipin forming 
mixed short-range and long-range crosslink spacers, a reaction to which the blue 
pigmentation created by genipin is attributed [43, 98, 99].   
Many other chemicals, including  tannic acid, hexamethylene diisocyanate,  
glutaraldehyde, and dicumyl peroxide have been used in scientific research as 
crosslinking agents for recombinant elastin proteins [43].  However, one of the most 
compelling features of genipin is that its efficacy is comparable with that of 
glutaraldehyde, while the cytotoxicity of genipin-crosslinked gels and membranes is 
lower than glutaraldehyde-crosslinked or carbodiimide-crosslinked counterparts [98, 
100].   
Most importantly, genipin crosslinking modifies the mechanical profile of 
recombinant elastin proteins.  It has been reported that after genipin crosslinking, 
recombinant elastin proteins form membranes whose approximated normalized modulus 
values (stress per strain per mass units) fall in range with values measured in aortic 










3.1. Protein Production  
 
3.1.1. Expression and Purification of Recombinant Elastin 
The recombinant elastin protein used in this study, LysB10 was cloned into the 
pET24-a expression plasmid (Invitrogen, Eugene, Oregon) and transformed in the E. coli 
expression strain BL21(DE3).  The design, cloning and transformation of the protein 
have been previously addressed by our group [35, 41]. Medium scale expression (16 L) 
were  prepared in Circle Grow (MP Biomedicals, Solon, Ohio) medium at a pH of 7.5, 
supplemented with kanamycin (50 µg/mL) (Fisher Scientific, Fair Lawn, New Jersey) and 
incubated at 37°C with shaking.    
Cells were harvested by centrifugation in sterile tubes at 1610 RCF for 20 
minutes at 4°C, and the expression medium was discarded.  The pellets were then 
resuspended in a total of 80 mL of cold sterile PBS (calcium and magnesium free) 
(HyClone, Logan, Utah).  Cell fracture was performed with three freeze/thaw cycles at -
80°C and 37°C.  The cells were thoroughly lysed through six sonication cycles, each 
consisting of 20-second bursts, followed by 20-second resting periods in an ice bath.  
The lysate was centrifuged at 1660 RCF for 10 minutes at 4°C (Allegra 64 R, Beckman-
Coulter, Fullerton, California) to recover any unbroken cells.  The unbroken cells were 
resuspended in cold sterile PBS and sonicated again. The LysB10 protein was purified 
by inverse transition cycling [101].  
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The cell lysate was centrifuged at 20,000g for 40 minutes at 4°C (Sorvall RC-6 
Plus model, Thermo Scientific, Ashville, North Carolina).  The supernatant was 
transferred to cold sterile tubes and poly(ethyleneimine) (PEI) (Sigma-Aldrich, St. Louis, 
MO) was added to a final concentration of 0.5% and mixed gently with the lysate.  After 
precipitation was observed, the lysate was centrifuged again at 20,000g for 40 minutes 
at 4°C for the removal of nucleic acids and other cell material.  The supernatant was 
transferred to new sterile tubes and NaCl was added to a final concentration of 2M.  The 
mix was, then, incubated at 25°C for 20 minutes to allow the elastin mimetic protein to 
coacervate and precipitate.  Next, the mix was centrifuged at 8000g for 15 minutes 
(Beckman, J2-HS, Palo Alto, California) to separate the protein precipitate from the 
supernatant, which was then carefully decanted without disturbing the pellet.  The 
protein was resuspended in cold, sterile PBS, shaken in a rotor incubator at 35 rpm for 
5-10 minutes.  The resuspended protein was centrifuged at 20,000g for 40 minutes at 
4°C for 40 minutes again.  The supernatant was transferred to 150 mL tubes and 
incubated at 25°C for 20 minutes.  The mix was centrifuged at 8000g for 15 minutes, and 
the precipitate resuspended in cold PBS.  This cycle of hot (25°C) and cold (4°C) spins 
was repeated until no contaminant pellet was observed after the cold spin.  The number 
of cycles necessary was usually 8 or 9 and ended with a hot spin and resuspension.   
Endotoxin removal required multiple sodium hydroxide (NaOH) treatments.  
Sterile NaOH (Sigma-Aldrich, Steinheim, Switzerland) was added to the resuspended 
protein to a final concentration of 0.4 N and mixed gently by hand.  Then, sterile sodium 
chloride was added to a concentration of 2 M.  These two last steps were performed 
under a cell culture hood and sterile techniques were employed.  The protein was 
precipitated from solution at 25°C, and centrifuged at 8000g for 15 minutes at the same 
25 
 
temperature and resuspended in cold PBS (again, under sterile conditions).  The 
endotoxyn removal treatment was repeated a total of three times. 
Following the NaOH treatments, the protein solution was adjusted to pH 6-8.  
The solution was then sterile-desalted using PD-10 desalting columns (GE Healthcare 
Lifesciences, Piscataway, New Jersey) with molecular grade water (HyClone, Logan, 
Utah).  The end product was syringe-filtered through a 0.2 µm filter (Millipore, Billerica, 
Massachusetts).  Finally, solution was transferred into a 50 mL tube, frozen overnight at 
-80°C and lyophilized.  The expression and purification processes produced white 
fibrous protein at a yield of approximately 35 mg per liter of expression culture.   
 
3.1.2. Expression and Purification of Recombinant Fibronectin  
The recombinant fibronectin protein used in this study, FNIII7-10, was created by 
the Erickson group [54].  Using standard techniques, the DNA sequence coding for the 
protein was cloned into the XA3 expression vector plasmid (Pinpoint System, Promega, 
Madison, Wisconsin) by Petrie et al. [61] and kindly donated in plasmid form.  The 
cloning resulted in the incorporation of a biotin-binding tag domain at the N- terminus of 
the protein.  Type III domains 7 through 10 in fibronectin in addition with the biotin-
binding domain add up to a total protein size of 52 kDa. The plasmid was transformed 
into JM109 E. coli expression strain (Promega, Madison, Wisconsin) by heat-shock 
treatment, as indicated in the manufacturer's specifications.  After transformation, the 
cells were streaked onto LB agar plates (Beckton Dickinson, Sparks, Maryland) 
containing 100 mg/mL ampicillin (Sigma-Aldrich, St. Louis, Missouri).  Single colonies 
were screened for successful transformants by standard gel electrophoresis and 
isolated.  These colonies were then cultured overnight in LB broth with addition of 100 
µg/mL ampicillin and 2 µM d-biotin (final concentrations) (Sigma-Aldrich, St. Louis, 
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Missouri), shaking at 225 rpm at 37°C.  Overnight cultures were inoculated in a total of 2 
liters of culture medium (same as above), and incubated until aliquots of the cultures had 
an optical absorbance of at least 0.8 at a wavelength of 600.00 nm.  The cultures 
reached this point after approximately 5 hours.  Protein expression was induced with 
Isopropyl beta-D-1-thiogalactopyranoside (IPTG) (Sigma-Aldrich, St. Louis, Missouri), 
added to a final concentration of 100 µM and incubation for 4 hours shaking at 225 rpm 
at 37°C.   
Cells were harvested by centrifugation in sterile conical tubes at 1610 RCF for 20 
minutes at 4°C, the expression medium was discarded.  The cell pellets were stored at -
80°C.  The pellets were then resuspended in a total of 30 mL of PBS.  Cell fracture was 
performed with three freeze/thaw cycles at -80°C and 37°C.  For nucleic acid 
degradation, benzonase (Sigma-Aldrich, St. Louis, Missouri) and protease inhibitor 
cocktail (Sigma-Aldrich, St. Louis Missouri) were added to the cell resuspension.  The 
cells were thoroughly lysed through ten sonication cycles, each consisting of 15 second 
bursts, followed by 30 second rests in an ice bath.  Unbroken cells were removed by 
centrifugation at 3000g for 10 minutes and later at 13000 rpm for 20 minutes, in both 
instances, the temperature was kept at 4°C.  The supernatant was syringe-filtered 
through a 0.2 µm filter.  The volume of the lysate was reduced to approximately 15 mL 
using a 30,000 kDa pore-size centrifugal filter (Millipore, Billerica, Massachusetts).  The 
protein solution was purified by affinity chromatography using an immobilized avidin 
agarose resin (Softlink Soft Release Avidin resin, Promega, Madison, Wisconsin) , which 
makes use of the avidin-binding tag attached to the protein, in a gravity column.  For 
each purification, the column was washed with 8 volumes of PBS.  After a 30-minute 
incubation, 0.5 resin volumes of cell lyste solution were added to the column. 
 Contaminants unbound to the resin were washed off with the addition of 35 
volumes of PBS to the column.  Afterwards, 4 resin volumes of 4 mM biotin were added 
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to elute all the biotin and biotinylated protein bound to the resin.  The biotin excess was 
removed using 30 kDa centrifugal filters and PD-10 desalting columns.  The protein was 
expressed and purified giving a yield of ~1 mg/mL.  The protein purity was assessed at > 
98% by Western blotting and Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE).  
SDS-PAGE was performed on a 12% acrylamide gel (BioRad, Hercules, 
California) and total protein was visualized with Coomassie G250 (BioRad, Hercules, 
California).  Western blot analysis was performed by transfer to an nitrocellulose 
membrane (BioRad, Hercules, California) and probed with mouse fibronectin monoclonal 
antibodies (HFN7.1) (Developmental Studies Hybridoma Bank, Iowa City, IA) followed 
by Amersham ECL™-HRP (horseradish peroxidase) linked goat-anti-mouse secondary 
antibodies (GE Bioscience, Piscataway, New Jersey) or streptavidin-alkaline 
phosphatase (Strep-AP) (Promega, Madison, Wisconsin).  Bands were visualized by 
using an ECL Western blotting detection kit (GE Healthcare Lifesciences,) and Western 
Blue® stabilized substrate for alkaline phosphatase (Promega, Madison Wisconsin). 
 
3.2. Cell Adhesion Experiments 
 
3.2.1 Testing the Biological Activity of rFN 
For all the surfaces used in cell adhesion experiments, non-tissue culture treated 
96-well polystyrene plates were used (BD Falcon, Franklin Lakes, New Jersey).  For the 
initial assessments of the biological activity of FNIII7-10 (rFN), 100 µL of rFN or human 
plasma fibronectin (hpFN) (Invitrogen, Carlsbad, California) were added to each 
polystyrene wells and allowed to incubate overnight at 4°C.  Unless otherwise specified, 
the coating concentration of rFN and hpFN was 50 µg/mL.  After incubation, the wells 
were washed three times with PBS to remove non-adsorbed fibronectin.  The wells 
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were, then, blocked with 1% bovine serum albumin (Fisher Scientific, Fair Lawn, New 
Jersey) for one hour at room temperature.  Excess BSA was removed with three PBS 
washes.  Each fibronectin-coated well constituted an experimental sample.     
 
3.2.2. Preparation of LysB10 hydrogels 
Untreated LysB10 gels (UTG surfaces) were prepared by hydrating dry fibrous 
LysB10 to a concentration of 60 mg/mL. The protein becomes soluble at cold 
temperature, so hydration required incubation at 4°C for 20-40 minutes with occasional 
vortexing.  Bubbles were removed by centrifuging hydrated LysB10 at 13,000 rpm for 4 
minutes at 4°C.  For each experimental sample, 40 µL of hydrated LysB10 were 
carefully added to the bottom of a well in a 96-well polystyrene plate.  This was 
performed in a cold room, at 4°C, to keep the protein liquid and prevent it from gelling.  
The viscous protein was equally spread on the bottom of the wells carefully without 
forming bubbles. 
After laying the protein on the wells, the plates were incubated for one hour at 37°C to 
start protein gellation.  At the end of the incubation, 200 µL of genipin at a 6 mg/mL 
concentration in PBS were added.  The gels were allowed to crosslink overnight.  Any 
unreacted genipin was thoroughly removed by washing the gels with fresh PBS three 
times.  This triple PBS washing was repeated four times in the course of 12 hours for all 
the gel surfaces.  
 
3.2.3 Passive Adsorption and Stable rFN Incorporation onto LysB10 Surfaces 
 For gel surfaces coated with passively adsorbed fibronectin (PAG surfaces), 100 
µL of rFN solution were added on top of the gels, and the surfaces were incubated at 
room temperature overnight.  Unless otherwise specified, the rFN coating concentration 
was 20 µg/mL. 
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Surfaces consisting of genipin-crosslinked rFN onto LysB10 gels (GPX surfaces) 
were prepared by incubating a solution of the desired concentration of rFN (20 µg/mL, 
unless otherwise specified) on top of LysB10 gels (before crosslinking) overnight.  The 
following day, excess rFN was washed away with PBS, and 200 µL of genipin at a 6 
mg/mL concentration in PBS were added on top of the gelled surfaces to crosslink rFN 
and LysB10 together overnight.  Excess genipin was removed as previously described 
for untreated surfaces.  For stability experiments, surfaces were washed with PBS daily 
for 7 days before cell adhesion experiments. 
 
3.3. Cell Culture, Seeding and Quantification 
 
Human umbilical vein cells (HUVEC) (Lonza, Walkersville, Maryland) cultures 
were started with approximately 250,000 cells in endothelial cell growth medium (EGM-2 
BulletKit, Lonza, Walkersville, Maryland) in 75 cm2 flat culture flasks (BD Falcon, 
Franklin Lakes, New Jersey). The medium was replaced after 24 hours, the first time 
and, subsequently, after every 48 hours.  After reaching 90-100% confluence, the cell 
cultures were washed three times with calcium-free, magnesium-free PBS, and the cells 
were detached using a PBS-based cell dissociation solution (Millipore, Billerica, 
Massachusetts).  The cells were harvested by centrifugation at 2000 rpm for 7 minutes 
at 4°C (CR-312 model, Jouan, Winchester, Virginia).  The cells were resuspended with 
HUVEC serum-free medium and any cell clumps broken by gentle shaking and 
occasional pipette suction until the cells were individually separate.  Cells were seeded 
on protein-coated polystyrene wells and LysB10 gels at a number of 10,000 cells per 
well.   
For proliferation experiments, the cells were seeded at a number of 5,000 per 
well.  After two hours, the cell medium was switched, and fresh growth medium was 
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added on top of the cell-seeded surfaces.  Cells were allowed to proliferate for a total of 
48 hours.  After 2 hours and 48 hours (for proliferation experiments) of incubation, the 
cell medium was removed, and unadhered cells were washed away with PBS.  For cell 
fracturing, the plates were stored at -80°C overnight and thawed the following day.  The 
cells were lysed and quantified using the CyQuant ® Cell Proliferation Assay Kit 
(Invitrogen; Eugene, OR), following the manufacturer's instructions.  A CytoFluor® 
Series 4000 microplate reader (Applied Biosystems, Framingham, Massachusetts) was 
used to measure the fluorescence at an excitation of 485 nm and detection of 530 nm.   
 
3.4 Elisa and rFN Immobilization Efficiency 
 
An ELISA was used to determine the rFN immobilization efficiency.  The 
Fibronectin EIA kit (Takara Bio; Otsu, Shiga, Japan) was used for these assays. The 
assay uses 96-well plates coated with FN30-8 capture antibodies and FN12-8 detection 
antibodies labeled with peroxidase (POD).  These mouse antibodies, both directed to 
human fibronectin, were developed by Katayama et al. FN30-8 binds to a region 
encompassing amino acids in the FNIII8 and FNIII9 domains of fibronectin, between 153 
and 229 amino acids away from the RGD site.  FN12-8 antibodies bind to a region of 
fibronectin including amino acids in the FNIII10 and FNIII9 domains (not overlapping with 
FN30-8) [102].  This distribution assures that FN30-8 can be used to immobilize 
fibronectin without occluding the RGD or PHSRN sites, while these regions, so critical 
for cell-binding activity, can effectively be probed with FN12-8 antibodies.  The 
antibodies were also reported by Katayama to not compete with each other in ELISA 
[102].  Furthermore, the epitopes of these two antibodies in fibronectin are reproduced in 
rFN, proving the compatibility of this commercially available assay with our recombinant 
version of fibronectin.   
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The FN30-8 –coated wells were used to immobilize rFN in the creation of a 
standard curve.  GPX surfaces were prepared following the protocol explained before at 
different rFN concentrations. The assay was performed following the protocol specified 
by the supplier.  For the standards, 100 µL of rFN at various concentrations were added 
to FN30-8 –coated wells, incubated for 1 hour at 37 °C and washed with a PBS solution 
containing 0.1 % Tween 20.  For both standards and samples, FN12-8-POD conjugate 
solution was added to the wells.  The plates were incubated for 1 hour at 37°C, and the 
wells washed.  A buffered substrate solution containing hydrogen peroxide and 
tetramethylbenzidine (supplied by the manufacturer) was added and incubated for 15 
minutes at room temperature.  Finally, a 1N solution of H2SO4 was added to stop the 
reaction.  The resulting absorbance at 450 nm was measured in a plate reader 
(Multiskan Spectrum model, Thermo Scientific, Ashville, North Carolina).  
 
3.5. Immunostaining for Vinculin and Actin 
 
Culture slides (BD Falcon, Franklin Lakes, New Jersey) were added hpFN and 
rFN for passive adsorption, blocked with BSA and seeded with HUVEC as specified 
before (see section 3.2.1 and 3.3).  Similarly, hydrogel surfaces, untreated and rFN-
modified, were prepared on culture slides and seeded with cells.  Because of the 
interference of the blue coloration of genipin-crosslinked surfaces with the staining, the 
hydrogels were crosslinked with triglycidylamine, which produced transparent 
crosslinked surfaces.  The crosslinker was synthesized by Venkat Krishnamurthy 
(Chaikof Lab) according to the protocol published by Connolly et al [103].  After a two-
hour period of cell incubation, the surfaces were washed with PBS and fixed with 4% 
paraformaldehyde (PFA) for 10 minutes at room temperature.  The surfaces were 
permeabilized with a PBS solution containing 0.5% Triton X-100 for 10 minutes at room 
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temperatures.  The solution was removed, and the samples rinsed with a 100 mM 
glycine solution in PBS for 10 minutes at room temperature.  The samples were then 
incubated with blocking buffer (PBS, 0.2% Triton X-100, 6% serum match to secondary 
goat antibody) with shaking for 1 hour at room temperature.  For vinculin staining, mouse 
monoclonal antibody against human vinculin (Sigma-Aldrich, St. Louis, Missouri) was 
diluted in blocking buffer and incubated on the culture slides for one hour at room 
temperature with shaking.  Samples were rinsed with blocking buffer and PBS.  
Secondary biotinylated goat anti-mouse IgG (Invitrogen, Eugene, Oregon) (2.5 µg/mL in 
blocking buffer) were added and incubated on the samples for 45 minutes at room 
temperature with shaking.  After rinsing with PBS, the samples were added 2.5 µg/mL 
streptavidin-AlexaFluor 488 (Invitrogen) solution in PBS and allowed to incubate for 30 
minutes.  Cell nuclei were counterstained with Prolong gold mounting medium with DAPI 
(Invitrogen) and left to cure at room temperature protected from light for approximately 
24 hours before sealing with nail polish.   
For actin staining, AlexaFluor 568 phalloidin (Invitrogen) was diluted twenty-fold 
in PBS and added to the wells instead of primary vinculin antibodies.  To reduce 
nonspecific staining, 1% BSA (final concentration) was added to this last solution.  The 
samples were allowed to stain for 30 minutes.  The samples were then rinsed with PBS.  












4.1. Fibronectin and rFN Show Similar Biological Activity 
 
Recombinant fibronectin, FNIII7-10, was expressed and purified.  The purity was 
assessed with a standard SDS-PAGE at >98% (Figure 4-1A).  These PAGE results 
show a single noticeable band at the size expected for rFN (approximately 52 kDa).  The 
presence of rFN in the purified sample was verified with western blotting and the addition 
of streptavidin alkaline phosphatase marker (Strep-AP).  The marker binds to free biotin 
and to any biotin-binding molecule remaining after purification (Figure 4-1B).  Only three 
possible biotin components were expected to be present in the cell lysate from the 
expression strain of E.coli used for this protein: free biotin (MW 244 Da), biotin carboxyl 
carrier protein (BCCP, a component of Acetyl-CoA) (22.5 kDa) [104] and biotinylated 
rFN (52 kDa).   
Finally, identity of the purified recombinant expression product was confirmed by 
western blotting and immunostaining (Figure 4-1C).  HFN 7.1 mouse fibronectin 
monoclonal antibodies were used in this experiment as primary antibodies. This antibody 
maps to the cell-binding region of fibronectin between the ninth and tenth type III repeat, 
and it is capable of blocking cell adhesion to fibronectin [105].   Keselowski, Petrie and 
Garcia describe the correlation between HFN7.1 binding and the availability integrin-
binding sites in fibronectin and, therefore, fibronectin’s biological activity [61, 106].  The 
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results for all of the three tests, SDS-PAGE, Strep-AP and immunostaining showed a 
single dominant band at the expected size. 
The biological activity of rFN and its similarity with hpFN were assessed directly 
through cell adhesion assays.  Polystyrene surfaces were coated rFN and hpFN by 
passive adsorption.  HUVECs were seeded and the number of cells adhering to the 
protein-coated surfaces was measured.  Adherent cells were fixed and stained for 
vinculin and actin.  Morphological characteristics of cell adhesion were observed in both 
rFN- and hpFN-coated surfaces by immunostaining (Figure 4-2).   
The adhesion assay results (Figure 4-3, Mean ± S.D.; n=4), showed that rFN- 
and hpFN-coated surfaces have the same degree of cell-binding activity.  The 
adsorption of both proteins improves cell attachment onto an otherwise inert surface. 
The activity of rFN was further compared to that of hpFN by observing how 
protein coating concentration influences the biological activity of the surfaces in both 
cases.  Different concentrations of rFN were passively adsorbed onto polystyrene 
surfaces, and the number of cells adhering to these surfaces was measured (Figure 4-4, 
Mean ± S.D.; n=4).  The number of adhered cells reached a plateau after a coating 
concentration of 5 µg/mL, which is in agreement with results published for hpFN 
concentration gradients by Lightner and Erickson [107] and with results other results 








Figure 4-1. Purification of rFN.  (A) SDS-PAGE. (B) Western blot with streptavidin 
alkaline phosphatase marker.  (C) Western blot immunostained with HFN7.1 (fibronectin 


































Figure 4-2.  Immunostaining for cell adhesion activity to rFN and hpFN.  Polystyrene 
surfaces were coated with hpFN and rFN and seeded with HUVECs.  Adhered cells 
were fixed, permeabilized with 0.5% Triton X-100, stained for vinculin and for actin to 
visualize actin filaments and focal adhesions and counterstained with DAPI.  
20 µm 50 µm




























Figure 4-3. Cell-adhesive activities of rFN and hpFN compared.  The two fibronectin 
variant proteins were passively adsorbed onto polystyrene surfaces at a concentration of 
50 µg/mL.  Inert BSA-blocked polystyrene (BBP) surfaces were used as negative 
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Figure 4-4. Cell-adhesive activity of rFN at different coating concentrations. 
Recombinant fibronectin at different concentrations was passively adsorbed onto 
polystyrene wells.  Polystyrene surfaces were then blocked with BSA.  Cell adhesion to 











4.2. LysB10 Hydrogels Cannot Support Cell Adhesion 
 
In order to demonstrate that recombinant elastin hydrogels do not support cell 
adhesion on its own, LysB10 in soluble phase was added to polystyrene wells.  Gels 
were formed by allowing the soluble protein to coacervate at higher temperatures, and 
then chemically crosslinking them with genipin.  Unreacted genipin was thoroughly 
washed to ensure cell membrane proteins would not be crosslinked into the hydrogels 
and cell adhesion results would not be skewed.  No rFN was added to untreated gel 
(UTG) surfaces.  Crosslinked LysB10 gels showed low levels of cell adhesion in 
comparison with rFN-coated polystyrene, yet higher than untreated polystyrene (Figure 

































Figure 4-5. Cell adhesion to LysB10 hydrogels. HUVECs were seeded on genipin-
crosslinked LysB10 gels with passively adsorbed rFN (50 µg/mL) onto polystyrene (rFN 
column), BSA-blocked polystyrene (BBP) and on genipin-crosslinked LysB10 gels 










4.3. LysB10 Hydrogels Support Cell Adhesion in the Presence of rFN   
 
As proof of concept that rFN can improve the cell-adhesive activities of LysB10 
surfaces, rFN was passively adsorbed onto the surfaces.  To demonstrate that 
improvements in cell adhesion were due to the presence of rFN on the gels, the 
fibronectin variant was incubated at different concentrations.  Once again, an increase 
on rFN coating concentrations generated an increase in the number of cells adhered to 
otherwise more sterile surfaces (Figure 4-6, Mean ± S.D.; n=3-4).  HUVEC adhesion to 
LysB10 was low (though greater than to untreated BSA-blocked polystyrene), but greatly 
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Figure 4-6. Improvement of cell adhesion on LysB10 hydrogels in the presence of rFN.  
Different concentrations of rFN were used to coat LysB10 hydrogels.  Adherent cell 











4.4 LysB10 Can Be Stably Modified with the Incorporation of rFN 
 
Once it was observed that rFN could increase the adhesion of endothelial cells to 
LysB10, stable methods for modifying hydrogels were explored.  Prior to genipin 
crosslinking, rFN solutions were incubated on top of coacervated LysB10 gels.  Then 
genipin was added to crosslink rFN and LysB10 networks together.  The rFN 
immobilization efficiency was determined by means of an ELISA.  GPX surfaces were 
probed with POD conjugated fibronectin antibodies, and the absorbance was measured.  
The assay showed a hyperbolic relation between the rFN concentration coated on 
coacervated LysB10 prior to genipin addition and rFN effectively immobilized (Figure 4-
7, Mean ± S.D.; n=3).  Cell morphology characteristics associated with adhesion were 
identified by fixing adherent cells and staining them for actin.  Cells adhered to modified 
surfaces presented actin filaments traversing stretched cytoplasms.  In contrast, cells 
adhered to unmodified surfaces presented a round shape with actin dispersed 
throughout the cytoplasm (Figure 4-8). 
The cell adhesion levels of the rFN-LysB10 genipin crosslinked surfaces (GPX) 
were compared with passively adsorbed rFN onto LysB10 and rFN-free LysB10 
hydrogels.  The chemically modified surfaces showed the same cell-binding 
effectiveness as coated hydrogel surfaces.  The incorporation of rFN by means of 
chemical crosslinking or absorption greatly increased cell adhesion on hydrogels (Figure 
4-9, Mean ± S.D.; n=4).   
The effects of rFN concentration on the cell-adhesive ability of GPX surfaces 
were studied.  A dilution series of rFN was prepared and different concentrations were 
used during the incubation of coacervated LysB10 gels, prior to genipin crosslinking.  
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The relation between rFN concentration and cell adhesion shows a hyperbolic curve 
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Figure 4-7. Crosslinking efficiency of rFN onto LysB10 hydrogels.  Amounts of rFN 
immobilized in GPX surfaces were measured using a sandwich ELISA.  FN30-8 capture 
antibodies and HP12-8-POD conjugate detection antibodies were used for standard 













Figure 4-8.  Immunostaining for cell adhesion activity to untreated and modified 
hydrogels. Untreated and rFN-crosslinked gel surfaces were prepared as explained and 
seeded with HUVECs.  Adhered cells were fixed, permeabilized with 0.5% Triton X-100, 



























Figure 4-9. Cell adhesion to modified LysB10 hydrogels. HUVECs were seeded on three 
types of hydrogel surfaces: chemically modified rFN-LysB10 hydrogels (GPX), rFN 
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Figure 4-10. Cell adhesion to modified LysB10 hydrogels at different rFN concentration. 
Different concentrations of rFN were incubated on top of LysB10 prior to chemical 











The potential of modified hydrogels for endothelialization was further assessed 
by observing the surface's suitability to sustain cell proliferation.  GPX and PAG surfaces 
were prepared as previously specified.  Cells were seeded and incubated for a period of 
2 and 48 hours.  At t=2 hours, non-adhered cells were washed away and the adhesion 
(basal) medium was exchanged for HUVEC growth medium.  The adherent cell number 
was measured at t= 48 hours (Figure 4-11, Mean ± S.D.; n=3).  The proliferation rate 
was calculated by normalizing the cell number at 48 hours over the number of cells 
adhered to the surfaces at the beginning of the incubation period (t=2 hours).  Both 
surfaces showed a comparable proliferation rate.  The number of cells on both surfaces 
had more than doubled in the course of 48 hours of incubation. 
Finally, the superior stability of chemically modified hydrogels over coated 
hydrogels was verified by means of a prolonged surface incubation.  UTG, PAG and 
GPX surfaces were prepared and kept hydrated with PBS during seven days of 
incubation.  The PBS was replaced daily during that period.  At the end of the incubation, 
HUVECs were seeded as normal and adherent cell levels were measured.  The 
chemically modified surfaces retained their whole cell adhesive ability.  On the other 
hand, the adhesion levels on coated hydrogel surfaces dropped closed to the levels in 
unmodified gel surfaces, losing their ability to support cell adhesion (Figure 4-12, Mean ± 





























Figure 4-11. Endothelial cell proliferation on modified, coated and untreated hydrogels.  
HUVECs were seeded on chemically modified (GPX), rFN coated (PAG) and untreated 
(UTG) hydrogels.  Cells were allowed to adhere to the surfaces for the first two hours 
after seeding.  Non-adherent cells were washed away and growth medium was added 
on the hydrogels to allow for cell proliferation.  The proliferation rate at 48 hours after 





































Figure 4-12. Stability of the chemical modification of hydrogels. Three types of hydrogel 
surfaces were prepared: chemically modified rFN-LysB10 hydrogels (GPX), rFN coated 
(PAG) and untreated hydrogels (UTG). Prior to cell seeding, the gels were kept hydrated 
and in incubation for seven days.  Hydration medium was changed daily during that time.  














This work describes the chemical incorporation of a recombinant fibronectin 
protein into an elastic mimetic hydrogel.  Elastin was chosen as a substrate protein 
because of the role it plays in the mechanical profile of native vasculature [23, 33].  
Several forms of recombinant elastin have been developed based on well studied 
conserved amino acid repeat sequences in native elastin [36, 41].  One of the main 
appeals for the use of recombinant versions of elastin is the possibility of tuning 
macroscopic properties of the protein by changing its primary sequence [38] and well 
optimized purification protocols [101].  LysB10 is an amphiphilic version of this protein 
previously created and characterized by our group.  LysB10 was designed to include the 
crosslinking capabilities of native elastin and a coacervation point at physiologically 
relevant conditions [41]. 
FNIII7-10 was chosen for this study due to its well studied ability to reproduce the 
cell adhesive properties of human plasma fibronectin [108] by means of the inclusion of 
RGD, an important cell-binding peptide [54] and PHSRN a peptide sequence that plays 
a synergistic role to RGD in cell adhesion [60, 61].  While other groups have worked on 
the incorporation of small RGD-containing peptides, these show a significantly lower cell 
adhesive activity compared to the complete protein [108].  Grant and colleagues have 
shown that not only the presence of RGD and PHSRN is necessary to obtain complete 
cell adhesive activity, but that alterations in the positioning of these sites with respect to 
each other can reduce cell attachment, spreading and downstream signaling events in 
the cell [109].  This recombinant version of fibronectin was chosen over native 
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fibronectin due to the possibility of introducing modifications by means of genetic 
engineering.  One of these modifications was the addition of a biotin-binding domain by 
Petrie and colleges [61].  The addition of this domain allowed for a simplified purification 
of the protein with commercially available purification kits.  The engineered biotin-binding 
ability can also be used for specific, sensitive and facile detection,  quantification, as well 
as new forms of protein immobilization taking advantage of the well known biotin-
streptavidin interactions [110].  This last concept was explored by McDevitt and 
colleagues.  RGD-containing recombinant fibronectin was cloned into recombinant 
streptavidin.  The resulting fibronectin-streptavidin protein was immobilized onto 
polystyrene surfaces blocked with biotinylated BSA, which effectively increased cell 
adhesion onto the surfaces in a manner dependent on the concentration of the 
recombinant protein [111]. 
Immunostaining for vinculin and actin indicate that cells adhered to rFN and to 
hpFN present the same morphology.  Furthermore, these morphological features in the 
cells are characteristic of focal adhesion formation and cell spreading. Focal complexes 
are formed after the binding of fibronectin and integrin on the cell membrane.  
Fibronectin-integrin complexes are recruited and a signaling process takes place, 
resulting on the recruitment of vinculin and other proteins on the intracellular side of the 
membrane.   
The immunostaining results for surfaces coated with hpFN and rFN display a 
greater concentration of vinculin on discrete point locations, mostly on the periphery of 
the cell [75].  The distribution of vinculin in these images suggests the protein is being 
recruited for the formation of focal adhesions.  Actin staining shows a fibrous mesh 
formed across a stretched cytoplasm on hpFN and rFN surfaces.  This morphology is 
expected from the polymerization of actin and the formation of stress fibers as the cell 
54 
 
binds to fibronectin on a rigid substratum and spreads.  The same actin morphology was 
observed when cells adhered to modified LysB10 surfaces were stained with phallopoid, 
indicating cell adhesion events.  As expected, cells adhered to hydrogels that did not 
present rFN remained rounded in shape and did not form a fibrous mesh of actin fibers. 
Bix et al. performed reported that endorepellin (the C-terminal domain of the 
heparan sulfate proteoglycan perlacan) and one of its modules are capable of disrupting 
focal adhesion formation and actin stress fibers.  Their immunostaining results constitute 
a good source of comparison with those obtained in this study.  Untreated controls and 
cells after a 3-hour recovery show vinculin and actin morphologies similar to the results 
obtained in this study and described above.  In contrast, cells exposed to endorepellin 
and fixed without allowing for recovery show vinculin dispersed throughout the 
cytoplasm rather than concentrated on focal adhesions.  Similarly, actin is not present in 
the form of filaments, but it is, instead, spread throughout the cytoplasm.  Nevertheless, 
actin seems to concentrate on intercellular junctions rather than on focal adhesions 
[112]. 
  In this study, genipin was the crosslinking agent of choice for the chemical 
crosslinking of LysB10 hydrogels and the incorporation of rFN.  Glutaraldehyde is the 
most commonly crosslinking agent for proteins [100], including elastin mimetic proteins 
[41, 92].  Genipin has been reported to have efficacy levels similar to glutaraldehyde with 
a much lower cytotoxicity [43].  The mechanical enhancements glutaraldehyde produces 
on LysB10 have been extensively documented by Sallach and colleges.  Their findings 
include a doubling of the material's Young modulus, increases in the ultimate tensile 
strength and decrease of its strain at failure [41].  Genipin crosslinking of EP20-24, 
another elastin-mimetic protein developed by the Keeley group [40], has produced 
membranes whose normalized modulus values fall in range with values measured in 
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aortic elastin [43].  In comparison with LysB10, however, the sequence EP20-24 is 
shorter and richer in crosslinkable amino acid residues.  It is necessary to perform 
mechanical tests on genipin-crosslinked LysB10 hydrogels.  While a stiffening of the 
material is clearly expected, the tests will determine if the mechanical profile of the 
crosslinked hydrogels is comparable to natural elastin vasculature. 
One of the hypotheses of this study was that rFN has comparable biological 
activity to that of hpFN.  The results obtained in this study show that both proteins, when 
passively adsorbed to polystyrene surfaces, provide increased support for cell adhesion 
at comparable levels.  These results are in agreement with those shown by Erickson 
[107] and by Garcia [108] in direct comparison.  Furthermore, in this work the same 
hyperbolic relation is shown between the coating concentration of rFN and the number of 
adherent cells as published by Erickson [107].  In both studies, cell adhesion plateaus at 
a concentration of approximately 5 µg/mL. 
It was observed in this research that LysB10 hydrogels do not support cell 
adhesion.  While peptide sequences with chemotactant effects over fibroblasts and 
monocytes have been identified in natural elastin [113], recombinant elastin substrates 
have generally not been reported as capable of supporting cell adhesion [64, 114].  The 
only exceptions to these reports are cases where cell-binding peptides derived from 
other ECM proteins have been incorporated into the primary sequence of the elastin-
mimetic protein [93, 94] or when a spatially (rather than biochemically) suitable 
environment has been created for cells by means of electrospinning a fibrillar network 
[29].  Urry and coworkers, stated that preliminary data on certain elastin mimetic proteins 
(specifically, VGVGP repeats) indicated they were refractive to cell adhesion, opting, 
instead on the incorporation of RGD sequences into the protein for cell-binding effects 
[115].   
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Hydrogels coated with rFN and covalently modified with rFN initially had 
comparable levels of cell adhesion.  A stability test was performed to determine whether 
these forms of rFN presentation lead to stable surface functionalization.  After a long 
incubation period, only surfaces chemically modified with rFN retained biological activity. 
To our knowledge, protein adsorption onto elastin mimetic substrates has not been 
studied.  Due to the high hydrophobicity of elastin [36, 44] and its recombinant analogs, 
however, high levels of protein adsorption are possible on the basis of lower interfacial 
energies towards the biological surroundings than to an aqueous medium [116].  As one 
of her controls Kaufmann reports negligible levels of cell adhesion onto an elastic 
mimetic surface incubated in the presence (but not chemically coupled) to an RGD-
containing peptide [64].  This however, is an oligopeptide of 6 residues, compared to the 
52 kDa size of rFN, which could account for the negligible levels of cell adhesion to 
unmodified substrates.    
The experiments on the stability of chemical modification showed that surfaces 
coated with rFN do not retain biological activity after long incubation prior to cell seeding.  
This indicates that only chemical modification provides a stable and reliable method for 
increasing endothelialization of LysB10 hydrogels.  Chemical immobilization holds 
several advantages over diffusible passive adsorption from a biomaterial design 
standpoint.  Even though cell-binding peptides have been used to coat inert surfaces 
and produce adhesive substrates in the short term [65], passive adsorption is not 
suitable for materials exposed to protein solutions, such as cell culture medium for long 
times, since desorption and proteolysis of the non-covalently bound protein can occur in 
addition to competitive adsorption with serum proteins [87, 117]. Covalent bonding is 
stronger and more stable than the interactions holding passively adsorbed peptides onto 
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a surface, which can be overcome by shear forces, competitive adsorption with other 
proteins and proteolysis [88].   
During the chemical modification of hydrogels, genipin crosslinks rFN proteins 
coating coacervated gels.  Excess protein (not adsorbed onto the gels) was removed by 
washing prior to the addition of genipin.  The effects of protein concentration on cell 
adhesion with passively adsorbed rFN and chemically modified surfaces show the same 
hyperbolic relation.  Both curves plateau at rFN concentrations of approximately 20 
µg/mL.  This approach could, ultimately, achieve the stable blocking of the hydrogel 
surfaces with cell-binding proteins.   
The rFN crosslinking efficiency was assessed by ELISA.  The assay further 
supports the observation of concentration-dependent functionalization of LysB10 as 
seen on coated and modified hydrogels.  Protein concentration and effective 
immobilization displays a hyperbolic relation similar to that seen between concentration 
and cell adhesion.  The ELISA results in this study are in agreement with results 
published by Garcia et al., who also report this hyperbolic relation [61].  Furthermore, the 
maximum amount of rFN immobilization per surface area in this study is in the same 
order of magnitude as that reported by Petrie (~3000 ng/cm2 and ~6500 ng/cm2, 
respectively), though a different crosslinking method was used.  These results are 
comparable to reports by Zhang et al, who immobilized hpFN onto aminized PET using 
glutaraldehyde as the crosslinking agent.  They obtained the equivalent of approximately 
45 femtomoles of immobilized hpFN at a concentration of 30 µg/mL [118].  Roughly the 
same result was obtained in the ELISA performed for this study when differences in 
molecular weight of rFN and hpFN (52000 and 440000, respectively) are taken into 
account.   
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Another approach taken for the immobilization of recombinant fibronectin 
proteins onto substrates was that taken by McDevitt et al.  Fibronectin-streptavidin 
recombinant protein was successfully immobilized onto polystyrene sufaces blocked with 
biotinylated BSA.  Rat aortic endothelial cell adhesion showed not the hyperbolic relation 
to protein concentration observed in this study with HUVECs, but instead described a 
sigmoidal curve.  Cell adhesion plateaus at a protein concentration similar to modified 
surfaces in this study (~ 14 and 20 µg/mL respectively) [111].  McDevitt reports cell 
adhesion in absorbance levels rather than cell number, so more specific comparisons 
about cell adhesion levels cannot be made.  It is important to notice, however, that the 
fibronectin-derived RGD sequence incorporated into this protein is only 8 amino acids 
long (compared with 369 in rFN) and does not contain the PHSRN synergy site.   
Tirrell and coworkers have taken a different approach to the incorporation of 
fibronectin segments onto elastin-mimetic proteins [16, 92-94].  Instead of chemical 
immobilization, they have opted for engineering fibronectin peptide segments directly 
into the primary sequence of their recombinant elastin segment.  One of the advantages 
of this approach is that fibronectin grafting efficiency is directly controlled by the 
frequency cell-binding sequences repeat in the protein design in comparison with a more 
difficult control of crosslinking reactions.  On the other hand, Liu and Tirrell, inserted only 
RGD sequences in their protein [93], while the PHSRN synergistic site, and in the 
correct positioning, is required to elicit the full effect of cell adhesion in both efficacy and 
signaling cascade activity levels, [108, 109].  In addition, access to the cell-binding site is 
limited.  The RGD peptide is presented only at surface level and with very limited 
mobility.  With the crosslinking of rFN onto hydrogels, the length of the protein, 
approximately 140 angstroms [59] if grafted  from near the n-terminus, serves as spacer 
and increases mobility, thereby increasing the access to the cell binding sites. 
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In this study, elastin mimetic surfaces were successfully functionalized with 
recombinant fibronectin.  The unmodified surfaces initially showed an inability to support 
cell adhesion.  Chemical crosslinking of rFN onto these substrates conferred elastin 
mimetic hydrogel sufaces with the ability to support cell adhesion and proliferation.  The 
biological activity of rFN was studied and compared with natural human plasma 
fibronectin prior to any chemical incorporation.  It was observed that rFN promotes 
similar levels of cell adhesion as natural fibronectin.  Furthermore, the relation between 
cell adhesion and protein concentration was determined to be similar for recombinant 
and for natural fibronectin.  HUVECs showed the same morphology when adhered to 
inert surfaces coated with either type of fibronectin.  Later, rFN was implemented on 
LysB10 hydrogels, where surface coating promoted cell adhesion and proliferation.  
Finally, rFN was chemically immobilized onto the hydrogels.  The same biological effects 
were observed in modified and coated surfaces.  Adhered cells also showed the 
morphology characteristic of cell adhesion.  The immobilization efficiency of the 
technique used in this study was found to be comparable with others reported in the 
literature.  Chemical immobilization, unlike passive adsorption, proved to be a stable 
form of elastin mimetic hydrogel functionalization for promoting endothelialization. 
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